

Date: 10<sup>th</sup> January, 2018

To Compliance Department Metropolitan Stock Exchange of India Limited 4th Floor, Vibgyor Towers, Plot No. C 62, G Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098

# <u>Sub:</u> Submission of Corporate Governance Report under regulation 27(2)(a) for the quarter ended December 31, 2017

Dear Sir/Madam,

Please find enclosed herewith the Corporate Governance Report for the quarter ended December 31, 2017 under regulation 27(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Request to update your records.

Thanking You.

Yours faithfully,

For Jagadistana Pharmaceutical Works Limited

Se 673-0

Swapan Sickar () Managing Director DIN: 05149442

**Encl:** As above

JAGADISHWAR PHARMACEUTICAL VORKS LIMITED CIN: L24232AS1987PLC002803

Regd. Off.: 205, Haribol Roy Market, 2<sup>nd</sup> Floor, A.T.Road, Guwahati -781001 Corp. Off.: 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053 Website: jagadishwarpharma.com E\_mail ID: jpwltd@yahoo.com Phone No.: +91 7890586947

## Format to be submitted by listed entity on quarterly basis

- 1 Name of Listed Entity : Jagadishwar Pharmaceutical Works Limited
- 2 Quarter ending : **31<sup>st</sup> December**, **2017**

I. Composition of Board of Directors									
Title (Mr. / Ms)	Name of the Director	PAN <sup>s</sup> & DIN	Category (Chairperson /Executive/N on- Executive/in dependent/N ominee) <sup>&amp;</sup>	Date of Appointmen t in the current term /cessation	Tenure*	No of Directorshi p in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	
Mr.	Swapan Sarkar	BSCPS 6769R & 051494 42	Executive/ Non- Independe nt	21.05.2012	N.A.	8	3		
Mr.	Partha Chakra borty	AGSPC 2105N & 019955 91	Non- Executive/ Independe nt	01.08.2015	N.A.	8	3	2	
Smt	Kakali Ghosh	BPZPG 8544J & 07188585	Non- Executive/ Independen t	01.08.2015	N.A.	8	3	1	
<sup>&amp;</sup> Cate	gory of dir	ectors mean	ns executive/r	be displayed on the dis	/independe		Exchange if a director fits		

\* to be filled only for Independent Director. Tenure would mean total period from which Independent director is serving on Board of directors of the listed entity in continuity without any cooling off period.

#### II. Composition of Committees

II. Composition of Committees						
Name of Committee	Name of Committee members	Category				
		(Chairperson/Executive/Non-				
		Executive/independent/Nomi				
		nee) <sup>\$</sup>				
1. Audit Committee	Mr. Swapan Sarkar	Member/ Executive/ Non-				
		independent				
	Mr. Partha Chakraborty	Chairman / Non-Executive/				
		Independent				

			Smt. H	Kakali	Ghosh	l	Member/ Non-		
							Executive/Independent		
2. Nomination & Remuneration Committee				wapan	Sarkar		Member/ Executive/ Non- ndependent		
				Mr. Partha Chakraborty			Chairman/ Non-Executive/		
				Smt. Kakali Ghosh			Independent		
							Member/ Non-		
	•	(*6					Executive/Independent		
3. Risk Management Co	ommittee	e(1f	Not Applicable			ſ	Not Applicable		
	applicable)				Contron		Member/ Executive/ Non-		
4. Stakeholders Relation Committee'	isnip		Mr. Swapan Sarkar				ndependent		
Committee			Mr. Partha Chakraborty				Member/ Non-Executive/		
			1011.10	Mr. Partha Chakraborty			independent		
			Smt. F	Kakali	Ghosh		Chairman/ Non-		
				Shit. Kakan Onosh			Executive/Independent		
<sup>&amp;</sup> Category of directors 1	neans ex	cecutive/r	l 10n-exe	cutive	/independent/				
more than one category									
III. Meeting of Board		_	1	U		1			
Date(s) of Meeting (if a	ny) in	Date(s)	of Mee	ting (i	f any) in the	Maxin	timum gap between any two		
the previous quarter		relevant	-		.,		ecutive (in number of days)		
14.08.2017		14.11.2	017				lays		
IV. Meeting of Commi	ittees	I							
Date(s) of meeting of	1	er require	ement	Date	(s) of meeting	g of the	Maximum gap between		
the committee in the	of Quo	rum met	committee in the				any two consecutive		
relevant quarter	(details	5)	previous quarter				meetings in number of		
							days*		
14.11.2017	Yes			14.08.2017			93 days		
		torily be gi	iven for a	ren for audit committee, for rest of the committees giving this					
information is optional									
V. Related Party Tran		5			Complia		(XZ = (XZ = (XZ = (XZ = ))))		
Subject				Compliance si			us (Yes/No/NA) <sup>refer note below</sup>		
Whether prior approval of audit committee				e obtained N/A					
Whether shareholder approval obtained for									
RPT									
Whether details of RPT entered into pursu									
omnibus approval have	been rev	viewed by	Audit /						
Committee									
Note	~								
1In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A For									
example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N A" may									
may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.									
2 If status is "No" details of non-compliance may be given here.									
VI. Affirmations				-					
	ard of Di	rectors is	in terms	s of SE	BI (Listing ob	ligation	s and disclosure requirements)		
Regulations, 2015. 2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure									
requirements) Regulations, 2015									
a. Audit Committee									
b. Nomination & remuneration committee									

c. Stakeholders relationship committee

- d. Risk management committee (applicable to the top 100 listed entities)
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of Board of Directors may be mentioned here:

## For Jagadistinar Pharmaceutical Works Limited

Swapan Sockar of Managing Director DIN: 05149442

## Note:

Information at Table I and II above need to be necessarily given in 1st quarter of each financial year. However if there is no change of information in subsequent quarter(s) of that financial year, this information may not be given by Listed entity and instead a statement "same as previous quarter" may be given.